

Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis:  
Immunogenetics, Clinical Features, and Survival Analysis

J Rheumatol 2011;38;1534

<http://www.jrheum.org/content/38/7/1534.2>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

**Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis**

Sharif S, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron M, the Canadian Scleroderma Research Group, Furst DE, Khanna DK, Del Junco DJ, Molitor JA, Schioppa E, Phillips K, Seibold JR, Silver RM, Simms RW, Genisos Study Group, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC. Anti-fibrillarin antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis. *J Rheumatol* 2011 August. In the Results section, under the heading "Clinical features," the first sentence should read as follows. AA SSc patients with AFA were younger at disease onset ( $p = 0.004$ ) but sex, disease type, and duration were not significantly different compared to AA SSc patients without AFA. We regret the error.  
doi:10.3899/jrheum.110071C1